Strategic Analysis of Antiviral Drug Development for Viral Hepatitis and HIV/AIDS

Strategic Analysis of Antiviral Drug Development for Viral Hepatitis and HIV/AIDS

Persistent Unmet Need Fuels Antiviral Drug Development for Bloodborne Pathogens

RELEASE DATE
26-Mar-2013
REGION
Global
Research Code: 9837-00-57-00-00
SKU: LS00241-GL-MR_17652
AvailableYesPDF Download

$1,500.00

Special Price $1,125.00 save 25 %

In stock
SKU
LS00241-GL-MR_17652

$1,500.00

$1,125.00save 25 %

DownloadLink
ENQUIRE NOW

Description

This research service focuses on antiviral/antiretroviral therapeutics for the treatment of infection with blood-borne pathogens of current global interest, specifically viral hepatitis and HIV/AIDS. A product and pipeline assessment is provided for marketed and investigational products and combination regimens for the treatment of HBV, HCV, and HIV infection. Segmentation by drug class is provided along with additional supporting information such as clinical trial timelines and results, historical and projected launch timelines, and epidemiology.

Table of Contents

Executive Summary

Methodology and Scope

Introduction

HBV Antiviral Market

HCV Antiviral Market

HIV Antiretroviral Market

Conclusions and Recommendations

Appendix

The Frost & Sullivan Story

Related Research
This research service focuses on antiviral/antiretroviral therapeutics for the treatment of infection with blood-borne pathogens of current global interest, specifically viral hepatitis and HIV/AIDS. A product and pipeline assessment is provided for marketed and investigational products and combination regimens for the treatment of HBV, HCV, and HIV infection. Segmentation by drug class is provided along with additional supporting information such as clinical trial timelines and results, historical and projected launch timelines, and epidemiology.
More Information
No Index Yes
Podcast No
Author Deborah Toscano
WIP Number 9837-00-57-00-00
Is Prebook No